-
In the post-"National Talk" era, we have passed the original research instead of the countercurrent
Time of Update: 2022-04-16
Medical insurance negotiation comprehensively uses decision-making tools such as pharmacoepidemiology, pharmacoeconomics, and health technology evaluation, starting from the clinical value of drugs and the unmet needs of patient groups, and taking the affordability of medical insurance funds and drug cost-effectiveness ratio as external and internal price constraints respectively .
-
At the beginning of the new year, Huadong Medicine is betting on ADC, Chia Tai Tianqing is smashing antibody drugs, and big pharmaceutical companies are getting together in transformation and R&D. Why do they want to?
Time of Update: 2022-04-16
These big pharmaceutical companies, represented by Huadong Medicine and Chia Tai Tianqing, are increasing their efforts in independent development and external cooperation, laying out characteristic innovative drugs, and aiming at the professional track .
-
80% of the bids were renewed, with ups and downs. The prices of pemetrexed and dexmedetomide dropped sharply, and the results of the centralized procurement in the Yangtze River Delta were released.
Time of Update: 2022-04-16
2. The price has gone up and down On the basis of the national procurement price, the price of the selected enterprises for the renewal of the bid has dropped significantly .
-
Notice of the State Food and Drug Administration on Issuing the Catalogue of Generic Drug Reference Preparations (The 52nd Batch) (No. 16 of 2022)
Time of Update: 2022-04-16
After being reviewed and confirmed by the Expert Committee on the Consistency Evaluation of Generic Drug Quality and Efficacy of the State Drug Administration, the catalogue of generic drug reference preparations (the fifty-second batch) is hereby released .
hereby notified .
-
Huadong Medicine 2 major BD deals in 7 days!
Time of Update: 2022-04-16
Based on a number of BD transactions, Huadong Medicine has gradually formed a global ADC R&D ecosystem, and built a world-class independent R&D industry platform in the ADC field to continuously develop differentiated ADC innovative drugs .
-
NMPA newly revised the "Quality Management Practice for Clinical Trials of Medical Devices", which will be implemented from "May 1st"
Time of Update: 2022-04-16
It is reported that in 2016, the former State Food and Drug Administration, together with the former National Health and Family Planning Commission, issued the "Quality Management Practice for Clinical Trials of Medical Devices" (CFDA Order No.
-
Guangdong Provincial Drug Trading Center issued a notice: 87 major varieties began to be purchased in volume
Time of Update: 2022-04-16
(3) The content of the objection feedback materials submitted by the enterprise should be true, valid, clear and complete, targeted and unambiguous, and legal and valid evidence materials (including but not limited to certification documents stamped with the official seal of the provincial drug procurement department, winning bids) should be provided in accordance with laws and regulations.
-
Whoever wins the new crown wins the world!
Time of Update: 2022-04-16
With the great success of the new crown vaccine product Spikevax, Moderna’s market value was close to $200 billion in August 2021, and it has more than 20 times in one year .
-
Jimin Trusted lgE antibody drug IND approved by CDE
Time of Update: 2022-04-16
Its research and development pipeline covers biological macromolecular innovative drugs, chemical small molecule innovative drugs, innovative traditional Chinese medicine, complex Generic and high-end preparations are committed to making breakthroughs in the therapeutic fields of kidney disease, tumor, cardiovascular and cerebrovascular, respiratory system, anti-infection, pediatrics, pain, etc.
-
The National Health and Medical Commission publicly solicits opinions on the "Working Plan for the Temporary Import of Drugs Urgently Needed in Clinical Practice"
Time of Update: 2022-04-16
Department of Pharmaceutical Affairs, National Health Commission March 29, 2022 attachment1 Work Plan for Temporary Import of Drugs Urgently Needed in Clinics (Draft for comments) In order to further improve the drug supply guarantee policy and meet the people's specific clinical urgent needs for drug use, this plan is hereby formulated in accordance with the relevant provisions of the "Pharmaceutical Administration Law of the People's Republic of China" .
-
CDE Releases the 56th Batch of Chemical Generic Drug Reference Preparations Solicitation Notice
Time of Update: 2022-04-16
Center for Drug Evaluation, State Drug Administration March 1, 2022 Original attachment: [1] "Catalogue of Reference Preparations of Chemical Generic Drugs (The Fifty-sixth Batch)" (Draft for Comment) (1) [2] Application form for objection to chemical generic drug reference preparations If this article violates your rights, please contact us .
-
A large number of pharmaceutical companies in Shanghai press the pause button
Time of Update: 2022-04-16
01 A large number of pharmaceutical companies in Shanghai were closed and managed From 5:00 on March 28th, Shanghai Pudong New Area will implement closure and control management .
-
Roche launched a HER2-ADC price war, which domestic companies may stand out
Time of Update: 2022-04-16
On January 21, 2020, T-DM1 was launched in China for the adjuvant treatment of patients with HER2-positive early breast cancer with residual invasive disease after receiving taxanes combined with trastuzumab-based neoadjuvant therapy It has become the first approved HER2-ADC drug in China, opening a new era of antibody-drug conjugate (ADC) therapy in China .
-
Three normative documents including "Guidelines for Compiling Annual Self-Inspection Reports for Medical Device Quality Management System" were released
Time of Update: 2022-04-16
In order to strengthen the supervision of medical device production and ensure the safety and effectiveness of medical devices, in accordance with the relevant provisions of the "Regulations on the Supervision and Administration of Medical Devices" and "Measures for the Supervision and Administration of Medical Device Production", the State Food and Drug Administration has recently revised and issued the "Annual Self-inspection of the Medical Device Quality Management System".
-
Innovative drugs make Hansen a lot of money!
Time of Update: 2022-04-16
Reviews Since March 15, Pfizer's new crown oral drug Paxlovid was included in the latest version of the new crown pneumonia diagnosis and treatment plan, and it has been put into clinical use in areas of China where there are clusters of cases .
-
The CDE article is a small auxiliary material, and the wrong use can also lead to life!
Time of Update: 2022-04-16
At present, China only proposes specific GMP requirements for excipient manufacturers to ensure the quality of excipients, but has not yet established a complete risk assessment system and guidelines for excipients, especially for MAH .
-
Eli Lilly, BMS, Roche, AstraZeneca lead the most anticipated new drug launch in 2022
Time of Update: 2022-04-16
donanemab [company] Eli Lilly [indication] Alzheimer's disease [2026 sales forecast] $6 billion In June last year, Biogen’s Aduhelm (aducanumab) targeting beta amyloid received accelerated approval from the FDA, and Evaluate had predicted that the drug’s peak sales in 2026 would be about $4.
-
The four departments issued an announcement on the "Quality Management Specification for the Production of Chinese Medicinal Materials"
Time of Update: 2022-04-16
On March 17, 2022, the State Food and Drug Administration, the Ministry of Agriculture and Rural Affairs, the State Forestry and Grassland Administration, and the State Administration of Traditional
-
Top 10 global generic drug rankings in 2022
Time of Update: 2022-04-16
Viatris' product portfolio includes more than 1,400 approved molecules across a broad range of therapeutic areas, including non-communicable diseases and infectious diseases, including globally recognized brands, complex generic and branded drugs, biosimilar combinations and various non-communicable diseases Prescription consumer products .
-
Live preview uses customized excipients to meet new challenges in formulations
Time of Update: 2022-04-16
Thursday, February 24 14:00 - 15:00 IFF Pharmaceutical Solutions Dr.
Gao Hao , an application technology expert in the Asia-Pacific region will discuss with you
